Dworkin R H, Boon R J, Griffin D R, Phung D
Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, New York 14642, USA.
J Infect Dis. 1998 Nov;178 Suppl 1:S76-80. doi: 10.1086/514260.
New and previously reported analyses of the data from a placebo-controlled trial of famciclovir are reviewed in light of recently proposed recommendations for the analysis of pain in herpes zoster trials. The analyses examined the effect of famciclovir treatment on the duration of postherpetic neuralgia (PHN), which was defined as pain persisting after rash healing, pain persisting > 30 days after study enrollment, or pain persisting > 3 months after study enrollment; the baseline characteristics of patients in the famciclovir and placebo groups who developed PHN; the impact of famciclovir treatment on the duration of PHN, while controlling for significant covariates; and the prevalence of PHN at monthly intervals from 30 to 180 days after enrollment. The results of these analyses indicated that greater age, rash severity, and acute pain severity are risk factors for prolonged PHN. In addition, they demonstrated that treatment of acute herpes zoster patients with famciclovir significantly reduces both the duration and prevalence of PHN.
根据最近提出的带状疱疹试验疼痛分析建议，对泛昔洛韦安慰剂对照试验数据的新分析和先前报告的分析进行了回顾。这些分析考察了泛昔洛韦治疗对带状疱疹后神经痛（PHN）持续时间的影响，PHN定义为皮疹愈合后仍持续的疼痛、研究入组后持续超过30天的疼痛或研究入组后持续超过3个月的疼痛；发生PHN的泛昔洛韦组和安慰剂组患者的基线特征；在控制显著协变量的情况下，泛昔洛韦治疗对PHN持续时间的影响；以及入组后30至180天每月间隔的PHN患病率。这些分析结果表明，年龄较大、皮疹严重程度和急性疼痛严重程度是PHN持续时间延长的危险因素。此外，结果显示用泛昔洛韦治疗急性带状疱疹患者可显著降低PHN的持续时间和患病率。
